Abstract
Although α7 nicotinic acetylcholine receptors are considered potentially important therapeutic targets, the development of selective agonists has been stymied by the α7 receptor's intrinsically low probability of opening (Popen) and the concern that an agonist-based therapeutic approach would disrupt endogenous cholinergic function. Development of α7 positive allosteric modulators (PAMs) holds promise of avoiding both issues. N-(5-Chloro-2,4-dimethoxyphenyl)-N′-(5-methyl-3-isoxazolyl)-urea (PNU-120596) is one of the most effective α7 PAMs, with a mechanism associated, at least in part, with the destabilization of desensitized states. We studied the mechanism of PNU-120596 potentiation of α7 receptors expressed in Xenopus laevis oocytes and outside-out patches from BOSC 23 cells. We identify two forms of α7 desensitization: one is destabilized by PNU-120596 (Ds), and the other is induced by strong episodes of activation and is stable in the presence of the PAM (Di). Our characterization of prolonged bursts of single-channel currents that occur with PNU-120596 provide a remarkable contrast to the behavior of the channels in the absence of the PAM. Individual channels that avoid the Di state show a 100,000-fold increase in Popen compared with receptors in the nonpotentiated state. In the presence of PNU-120596, balance between Ds and Di is dynamically regulated by both agonist and PAM binding, with maximal ion channel activity at intermediate levels of binding to both classes of sites. In the presence of high agonist concentrations, competitive antagonists may have the effect of shifting the balance in favor of Ds and increasing ion channel currents.
Footnotes
This work was supported by National Institutes of Health National Institute of General Medical Sciences [Grant R01-GM57481]; and the National Institutes of Health National Institute on Aging [Grant T32-AG000196].
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
doi:10.1124/mol.111.074302.
-
ABBREVIATIONS:
- nAChR
- nicotinic acetylcholine receptor
- PAM
- positive allosteric modulator
- Popen
- probability of channel opening
- 5HI
- 5-hydroxyindole
- PNU-120596
- N-(5-chloro-2,4-dimethoxyphenyl)-N′-(5-methyl-3-isoxazolyl)-urea
- Di
- type II PAM insensitive desensitization
- Ds
- type II PAM sensitive desensitization
- ACh
- acetylcholine
- BTMPS
- bis-(2,2,6,6-tetramethyl-4-piperidinyl) sebacate
- TM2
- second transmembrane domain
- MLA
- methyllycaconitine
- DHβE
- dihydro-β-erythroidine
- TQS
- 4-(5-(4-chlorophenyl)-2-methyl- 3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide
- A-867744
- 4-(5-(4-chlorophenyl)-2-methyl- 3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide
- PNU-282987
- N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-chlorobenzamide.
- Received June 21, 2011.
- Accepted September 1, 2011.
- Copyright © 2011 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|